ARTICLE AD BOX
Douglas Ingram, president and main enforcement serviceman of Sarepta Therapeutics Inc., during the Forbes Healthcare Summit successful New York, US, connected Tuesday, Dec. 5, 2023.
Michael Nagle | Bloomberg | Getty Images
Shares of Sarepta Therapeutics plunged much than 30% connected Friday arsenic the aboriginal of its approved cistron therapy attraction appeared astatine risk.
The Food and Drug Administration volition petition that the institution voluntarily halt each shipments of the treatment, Elevidys, a idiosyncratic acquainted with the substance told CNBC.
Sarepta told CNBC it had not heard from the FDA.
Separately, FDA Commissioner Marty Makary told Bloomberg News the bureau is considering whether the company's cistron therapy should enactment connected the market.
The FDA has been investigating 2 diligent deaths tied to Elevidys. The institution besides reported a 3rd decease tied to a abstracted experimental cistron therapy.
The company's banal has present fallen much than 87% this year.
— CNBC's Angelica Peebles contributed to this report
This communicative is developing. Please cheque backmost for updates.
English (US) ·